NYSE:DHR

Danaher - DHR Stock Forecast, Price & News

$258.29

-3.86 (-1.47%)

(As of 09/30/2022 09:01 PM ET)

Add

Compare

Today's Range: $258.03
▼
$265.60
50-Day Range: $258.29
▼
$302.35
52-Week Range: $233.71
▼
$331.68

Volume: 2.67 million shs
Average Volume: 2.63 million shs
Market Capitalization: $187.89 billion

P/E Ratio: 30.42
Dividend Yield: 0.39%
Price Target: $321.75

Danaher MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.92 Rating Score
Upside/Downside: 24.6% Upside
$321.75 Price Target
Short Interest: Healthy
0.67% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -1.56
Upright™ Environmental Score
News Sentiment: 0.27
Based on 13 Articles This Week
Insider Trading: Selling Shares
$11.82 M Sold Last Quarter
Proj. Earnings Growth: 2.40%
From $10.40 to $10.65 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Multi-Sector Conglomerates Sector

6th out of 17 stocks

Process Control Instruments Industry

5th out of 12 stocks

3.5

Analyst's Opinion

Consensus Rating
Danaher has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $321.75, Danaher has a forecasted upside of 24.6% from its current price of $258.29.
Amount of Analyst Coverage
Danaher has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.67% of the float of Danaher has been sold short.
Short Interest Ratio / Days to Cover
Danaher has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Danaher has recently increased by 7.51%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Danaher has a dividend yield of 0.39%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Danaher has been increasing its dividend for 6 years.
Dividend Coverage
The dividend payout ratio of Danaher is 11.78%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Danaher will have a dividend payout ratio of 9.39% next year. This indicates that Danaher will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Danaher has received a 42.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Prenatal screening services", "Non-invasive prenatal testing services", "Point-of-care tests", "Diagnostic test kits", "Private genetic testing services", and "Clinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Danaher is -1.56.

1.8

News and Social Media Coverage

News Sentiment
Danaher has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Multi-Sector Conglomerates companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Danaher this week, compared to 9 articles on an average week.
Search Interest
Only 21 people have searched for DHR on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.
MarketBeat Follows
Only 22 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,823,179.00 in company stock.
Percentage Held by Insiders
11.20% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.27% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Danaher are expected to grow by 2.40% in the coming year, from $10.40 to $10.65 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Danaher is 30.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.34.
Price to Earnings Ratio vs. Sector
The P/E ratio of Danaher is 30.42, which means that it is trading at a more expensive P/E ratio than the Multi-Sector Conglomerates sector average P/E ratio of about 5.15.
Price to Earnings Growth Ratio
Danaher has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Danaher has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Danaher (NYSE:DHR) Stock

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Stock News Headlines

October 1, 2022 | americanbankingnews.com

Danaher Co. (NYSE:DHR) Receives $321.75 Average Target Price from Brokerages

September 30, 2022 | businesswire.com

$28.8 Billion Worldwide Cell Analysis Industry to 2027 - Featuring Agilent Technologies, BD Biosciences, Danaher and Illumina Among Others - ResearchAndMarkets.com - Business Wire

September 30, 2022 | finance.yahoo.com

Key Reasons to Retain Danaher (DHR) Stock in Your Portfolio

September 29, 2022 | benzinga.com

This Is What Whales Are Betting On Danaher - Danaher (NYSE:DHR) - Benzinga

September 29, 2022 | businesswire.com

North American Companion Diagnostics Industry to 2028 - Featuring Danaher, GE Healthcare, Genomic Health and Illumina Among Others - ResearchAndMarkets.com - Business Wire

September 29, 2022 | finance.yahoo.com

Danaher Corporation (NYSE:DHR) insiders sold US$389m worth of stock, possibly signalling a downtrend

September 29, 2022 | businesswire.com

Global Vitamin D Testing Market (2022 to 2027) - Featuring Abbott Laboratories, Biokit, bioMerieux and Danaher Among Others - ResearchAndMarkets.com - Business Wire

September 28, 2022 | benzinga.com

Global Spectrometry Market Report to 2031 - Players Include Thermo Fisher Scientific, Danaher, Agilent Te - Benzinga

September 27, 2022 | nasdaq.com

Ex-Dividend Reminder: National Research, National Healthcare and Danaher - Nasdaq

September 27, 2022 | nasdaq.com

Danaher (DHR) Stock Moves -0.98%: What You Should Know - Nasdaq

September 27, 2022 | businesswire.com

Global Bioprocess Analyzers Market Report to 2027 - Featuring Agilent Technologies, Danaher, Emerson Electric and Merck Among Others - ResearchAndMarkets.com - Business Wire

September 27, 2022 | americanbankingnews.com

Danaher Co. (DHR) To Go Ex-Dividend on September 29th

September 27, 2022 | finance.yahoo.com

Danaher (DHR) Stock Moves -0.98%: What You Should Know

September 23, 2022 | businesswire.com

Global Lab Supplies Market Report to 2029 - Featuring Waters, Thermo Fisher Scientific, Sartorius and Danaher Among Others - ResearchAndMarkets.com - Business Wire

September 21, 2022 | nasdaq.com

Top Stock Reports for Microsoft, Danaher & Raytheon Technologies - Nasdaq

September 21, 2022 | seekingalpha.com

Danaher Stock: Cash Flow Profile Is Stellar (NYSE:DHR) - Seeking Alpha

September 20, 2022 | benzinga.com

NIKE Price Target Cut By This Analyst; Also Benchmark Sees $325 For Danaher - bluebird bio (NASDAQ:BLUE), - Benzinga

September 20, 2022 | benzinga.com

Here's How Much You Would Have Made Owning Danaher Stock In The Last 5 Years - Danaher (NYSE:DHR) - Benzinga

September 20, 2022 | benzinga.com

How Is The Market Feeling About Danaher? - Danaher (NYSE:DHR) - Benzinga

September 20, 2022 | finance.yahoo.com

Danaher Schedules Third Quarter 2022 Earnings Conference Call

September 19, 2022 | finance.yahoo.com

Danaher (NYSE:DHR) sheds 4.6% this week, as yearly returns fall more in line with earnings growth

September 17, 2022 | washingtonpost.com

Adobe, Arconic fall; Humana, Danaher rise - The Washington Post

September 16, 2022 | benzinga.com

8 Analysts Have This to Say About Danaher - Danaher (NYSE:DHR) - Benzinga

September 16, 2022 | benzinga.com

Danaher (NYSE:DHR) – Danaher shares are trading higher after the company announced it intention to separa - Benzinga

September 16, 2022 | cnbc.com

Stocks making the biggest moves after hours: NextEra, Danaher, Rhythm Pharmaceuticals and more - CNBC

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Company Calendar

Ex-Dividend for 7/29 Dividend: 6/23/2022
Last Earnings: 7/21/2022
Dividend Payable: 7/29/2022
Ex-Dividend for 10/28 Dividend: 9/29/2022
Today: 10/03/2022
Next Earnings (Confirmed): 10/20/2022
Dividend Payable: 10/28/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Process control instruments
Sub-Industry: Industrial Conglomerates
Sector: Multi-Sector Conglomerates
Current Symbol: NYSE:DHR
CUSIP: 23585110
CIK: 313616
Web: www.danaher.com
Phone: (202) 828-0850
Fax: 202-828-0860
Employees: 80,000
Year Founded: 1984

Price Target and Rating

Average Stock Price Forecast: $321.75
High Stock Price Forecast: $370.00
Low Stock Price Forecast: $265.00
Forecasted Upside/Downside: +24.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.92
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): $8.49
Trailing P/E Ratio: 30.42
Forward P/E Ratio: 24.84
P/E Growth: 1.24
Net Income: $6.43 billion
Net Margins: 20.61%
Pretax Margin: 24.79%
Return on Equity: 18.57%
Return on Assets: 9.55%

Debt

Debt-to-Equity Ratio: 0.45
Current Ratio: 1.75
Quick Ratio: 1.32

Sales & Book Value

Annual Sales: $29.45 billion
Price / Sales: 6.38
Cash Flow: $13.59 per share
Price / Cash Flow: 19.00
Book Value: $58.65 per share
Price / Book: 4.40

Miscellaneous

Outstanding Shares: 727,445,000
Free Float: 645,971,000
Market Cap: $187.89 billion
Optionable: Optionable
Beta: 0.87

Social Links

Key Executives

Mr. Steven M. Rales (Age 71)
Co-Founder & Chairman

Mr. Rainer M. Blair (Age 58)
Pres, CEO & Director
Comp: $5.77M

Mr. Mitchell P. Rales (Age 65)
Co-Founder & Director

Mr. Matthew R. McGrew (Age 50)
CFO & Exec. VP
Comp: $2.68M

Ms. Angela S. Lalor (Age 57)
Part Time Advisor
Comp: $3.23M

Mr. Joakim Weidemanis (Age 53)
Exec. VP
Comp: $3.06M

Ms. Jennifer L. Honeycutt (Age 52)
Exec. VP
Comp: $2.44M

Mr. Christopher M. Bouda
Chief Accounting Officer

Dr. Jose-Carlos Gutierrez-Ramos Ph.D. (Age 58)
Sr. VP & Chief Science Officer

Mr. John Bedford
VP of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DHR Stock - Frequently Asked Questions

Should I buy or sell Danaher stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DHR shares.
View DHR analyst ratings or view top-rated stocks.
What is Danaher's stock price forecast for 2022?: 12 brokers have issued 12-month price targets for Danaher's stock. Their DHR share price forecasts range from $265.00 to $370.00. On average, they anticipate the company's stock price to reach $321.75 in the next year. This suggests a possible upside of 24.6% from the stock's current price.
View analysts price targets for DHR or view top-rated stocks among Wall Street analysts.
How have DHR shares performed in 2022?: Danaher's stock was trading at $329.01 at the beginning of 2022. Since then, DHR shares have decreased by 21.5% and is now trading at $258.29.
View the best growth stocks for 2022 here.
When is Danaher's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our DHR earnings forecast.
How can I listen to Danaher's earnings call?: Danaher will be holding an earnings conference call on Thursday, October 20th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Danaher's earnings last quarter?: Danaher Co. (NYSE:DHR) released its quarterly earnings data on Thursday, July, 21st. The conglomerate reported $2.76 EPS for the quarter, beating the consensus estimate of $2.35 by $0.41. The conglomerate had revenue of $7.75 billion for the quarter, compared to analysts' expectations of $7.29 billion. Danaher had a net margin of 20.61% and a trailing twelve-month return on equity of 18.57%. Danaher's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.46 EPS.
Read the conference call transcript.
How often does Danaher pay dividends? What is the dividend yield for Danaher?: Danaher announced a quarterly dividend on Tuesday, September 13th. Shareholders of record on Friday, September 30th will be given a dividend of $0.25 per share on Friday, October 28th. This represents a $1.00 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Thursday, September 29th.
Read our dividend analysis for DHR.
Is Danaher a good dividend stock?: Danaher (NYSE:DHR) pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.38%. The company has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 11.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 9.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?: 27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Danaher own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).
What is Danaher's stock symbol?: Danaher trades on the New York Stock Exchange (NYSE) under the ticker symbol "DHR."
How do I buy shares of Danaher?: Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Danaher's stock price today?: One share of DHR stock can currently be purchased for approximately $258.29.
How much money does Danaher make?: Danaher (NYSE:DHR) has a market capitalization of $187.89 billion and generates $29.45 billion in revenue each year. The conglomerate earns $6.43 billion in net income (profit) each year or $8.49 on an earnings per share basis.
How many employees does Danaher have?: The company employs 80,000 workers across the globe.
Does Danaher have any subsidiaries?: The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
How can I contact Danaher?: Danaher's mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The official website for the company is www.danaher.com. The conglomerate can be reached via phone at (202) 828-0850, via email at investor.relations@danaher.com, or via fax at 202-828-0860.

This page (NYSE:DHR) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Danaher - DHR Stock Forecast, Price & News

Danaher MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Danaher (NYSE:DHR) Stock

DHR Stock News Headlines

DHR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

DHR Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™